Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-year open-label lisdexamfetamine safety study in children and adolescents with ADHD
NL-OMON38374Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD), sponsored by Takeda. Primary endpoints: Long-term safety, Growth effects and 4 more. Started Sep 2011; status: active, not recruiting.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NL-OMON38374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38374.